China: GTJA pilots $39m round in antibody drug firm Mabworks

Chinese private equity firm Shenzhen GTJA Investment Group has piloted a $39 million (RMB270) series B round in Mabworks Biotech Co Ltd, a Beijing-based developer of gene engineering antibody medicines.

Continue reading this story with a subscription to DealStreetAsia.


Should your colleagues be reading this article too? Contact us for corporate subscriptions at